KARD on Nasdaq

Kardigan, Inc.

Kardigan, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.¹ It is headquartered in South San Francisco, California.¹

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

TickerKARD on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersSouth San Francisco, California¹
Incorporated inDE²
Business addressC/O Kardigan, Inc., 131 Oyster Point Blvd., Second Floor, South San Francisco, Ca 94080²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Corporate structure

Kardigan, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Kardigan, Inc.

PERCEPTIVE ADVISORS LLC Filed SCHEDULE 13D/A on Kardigan, Inc., latest Oct 1, 2026 (2 filings since Jun 25, 2026)
Anastasios Gianakakos Filed SCHEDULE 13G on Kardigan, Inc., latest Aug 13, 2026
Jay Edelberg Filed SCHEDULE 13G on Kardigan, Inc., latest Aug 13, 2026
FMR LLC Filed SCHEDULE 13G/A on Kardigan, Inc., latest Aug 7, 2026 (2 filings since Aug 6, 2026)
ARCH Venture Fund XIII, L.P. Filed SCHEDULE 13D on Kardigan, Inc., latest Jun 29, 2026
HRTG GPE, LLC Filed SCHEDULE 13G on Kardigan, Inc., latest Jun 29, 2026

Kardigan, Inc. South San Francisco, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Kardigan, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive officerAnastasios Gianakakos Jun 18, 2026 to now³
PresidentAnastasios Gianakakos Jun 18, 2026 to now³
Chief financial officerBrianne Jahn Jun 18, 2026 to now⁴

Board members and other officers (13)

Chief Strategy OfficerAndy Pasternak Jun 18, 2026 to now⁵
Chief Medical OfficerJay Edelberg Jun 18, 2026 to now⁶
Board memberAnastasios Gianakakos Jun 18, 2026 to now³
Board memberDavid P. Meeker Jun 18, 2026 to now⁷
Board memberDouglas E. Giordano Jun 18, 2026 to now⁸
Board memberJoseph Edelman Jun 18, 2026 to now⁹
Board memberKimberly J. Popovits Jun 18, 2026 to now¹⁰
Board memberPaul L. Berns Jun 18, 2026 to now¹¹
Board memberTimothy P. Walbert Jun 18, 2026 to now¹²
Board memberKeith Crandell Jun 24, 2026 to now¹³
Board memberKristina Burow Jun 24, 2026 to now¹³
Board memberRobert Nelsen Jun 24, 2026 to now¹³
General counselJohn B. Moriarty Jun 18, 2026 to now¹⁴

Timeline

Sep 30, 20268-K Executive or director change; Regulation FD disclosure¹⁵
Aug 11, 20268-K Results of operations¹⁶
Jun 23, 20268-K Bylaws or fiscal year changed¹⁷
Jun 18, 2026New chief executive Anastasios Gianakakos becomes CEO³

Calendar

Coming up

Nov 10, 2026Reports results for the quarter ending Sep/2026¹⁸

When it reported results

Aug 11, 2026Reported quarterly or annual results¹⁶

Drug trials and FDA: coming up

Dec 2026Phase 2 trial readout expected Phase 2 trial of Tonlamarsen in Hypertension: primary completion expected Dec 2026 (ClinicalTrials.gov NCT07511361).¹⁹
Sep 2027Phase 2/3 trial readout expected Phase 2/3 trial of danicamtiv in Symptomatic Genetic Dilated Cardiomyopathy: primary completion expected Sep 2027 (ClinicalTrials.gov NCT07210723).²⁰

Drug trials and FDA: recently

Jan 12, 2026Phase 2 trial completed Phase 2 trial of Tonlamarsen in Hypertension: primary completion Jan 12, 2026, no results posted yet (ClinicalTrials.gov NCT06864104).²¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

54 filings to the SEC since October 2021: 1 quarterly reports, 3 major events, 32 insider forms, 8 large holders, 10 other. The latest 20:

Oct 1, 20264 EDGAR
Oct 1, 20263 EDGAR
Oct 1, 2026SCHEDULE 13D/A EDGAR
Sep 30, 20268-K EDGAR
Aug 13, 2026SCHEDULE 13G EDGAR
Aug 13, 2026SCHEDULE 13G EDGAR
Aug 11, 202610-Q EDGAR
Aug 11, 20268-K EDGAR
Aug 7, 2026SCHEDULE 13G/A EDGAR
Aug 6, 2026SCHEDULE 13G EDGAR
Jul 13, 20264 EDGAR
Jun 29, 2026SCHEDULE 13G EDGAR
Jun 29, 2026SCHEDULE 13D EDGAR
Jun 25, 2026SCHEDULE 13D EDGAR
Jun 24, 20264 EDGAR
Jun 24, 20263/A EDGAR
Jun 24, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
Jun 24, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
Jun 23, 20268-K EDGAR
Jun 22, 20264 EDGAR

The 54 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Jun 22, 2026	HRTG PV, L.P.10% owner	Buy	3,125,000	$16.00	$50.0M	Form 4
Jun 22, 2026	BERNS PAUL LDirector	Buy	1,250,000	$16.00	$20.0M	Form 4
Jun 22, 2026	NELSEN ROBERTDirector	Buy	1,250,000	$16.00	$20.0M	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

PERCEPTIVE ADVISORS LLCSCHEDULE 13D/A, 2 filings Jun 25, 2026 to Oct 1, 2026²²
Anastasios GianakakosSCHEDULE 13G, 1 filing Aug 13, 2026²³
Jay EdelbergSCHEDULE 13G, 1 filing Aug 13, 2026²⁴
FMR LLCSCHEDULE 13G/A, 2 filings Aug 6, 2026 to Aug 7, 2026²⁵
ARCH Venture Fund XIII, L.P.SCHEDULE 13D, 1 filing Jun 29, 2026²⁶
HRTG GPE, LLCSCHEDULE 13G, 1 filing Jun 29, 2026²⁷

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 68. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Hrtg Gpe, LLC	16,917,034	$403.5M	16.3%	New
Fmr LLC	8,909,066	$212.5M	0.0%	New
Perceptive Advisors LLC	8,200,662	$195.6M	3.0%	New
Capital Research Global Investors	3,598,942	$85.8M	0.0%	New
Jpmorgan Chase & Co	1,790,734	$46.4M	0.0%	New
Alliancebernstein L.P.	1,534,837	$36.6M	0.0%	New
Liberty Mutual Group Asset Management Inc.	1,196,411	$28.5M	2.5%	New
Jennison Associates LLC	903,575	$21.6M	0.0%	New
Paradigm Biocapital Advisors LP	900,000	$21.5M	0.4%	New
Jupiter Topco LLC	749,703	$17.7M	0.0%	New
Massachusetts Financial Services Co /ma/	650,000	$15.5M	0.0%	New
Goldman Sachs Group Inc	644,969	$15.4M	0.0%	New
Deep Track Capital, LP	600,000	$14.3M	0.2%	New
Woodline Partners LP	413,980	$9.9M	0.0%	New
Franklin Resources Inc	400,021	$9.5M	0.0%	New
Montanova Capital, LLC	400,000	$9.5M	0.2%	New
Bank of New York Mellon Corp	377,758	$9.0M	0.0%	New
Catalio Capital Management, LP	312,500	$7.5M	1.4%	New
Principal Financial Group Inc	300,000	$7.2M	0.0%	New
Eventide Asset Management, LLC	300,000	$7.2M	0.1%	New
Braidwell LP	300,000	$7.2M	0.3%	New
UBS Group AG	267,760	$6.4M	0.0%	New
Peregrine Capital Management LLC	229,776	$5.5M	0.2%	New
Millennium Management LLC	223,065	$5.3M	0.0%	New
Integral Health Asset Management, LLC	200,000	$4.8M	0.2%	New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Kardigan, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARKardigan, Inc.¹
CIK0002123613
Employer ID (EIN)93-2994203¹
Filer status<br>emerging growth company¹
Incorporated inDelaware¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business addressC/O Kardigan, Inc., 131 Oyster Point Blvd., Second Floor, South San Francisco, CA 94080¹
Phone(415) 573-3220¹
Shares outstanding93,503,699 as of Aug 7, 2026²⁸
On EDGAR sinceMar 26, 2026¹
Filings54 in all: 4 (17), 3 (14), SCHEDULE 13G (4), 8-K (3), SCHEDULE 13D (2), 10-Q (1), 3/A (1), 424B4 (1)¹
All 19 form types
8-A12B (1), CERT (1), DRS (1), DRS/A (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-8 (1), SCHEDULE 13D/A (1), SCHEDULE 13G/A (1)
Latest filingsQuarterly report (10-Q) Aug 11, 2026
Latest 8-K (8-K) Sep 30, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARKardigan, Inc. filings on SEC EDGAR
2
SEC EDGARKardigan, Inc. filings on SEC EDGAR
3
SEC EDGARAnastasios Gianakakos, Chief executive officer
4
SEC EDGARBrianne Jahn, Chief financial officer
5
SEC EDGARAndy Pasternak, Chief Strategy Officer
6
SEC EDGARJay Edelberg, Chief Medical Officer
7
SEC EDGARDavid P. Meeker, Board member
8
SEC EDGARDouglas E. Giordano, Board member
9
SEC EDGARJoseph Edelman, Board member
10
SEC EDGARKimberly J. Popovits, Board member
11
SEC EDGARPaul L. Berns, Board member
12
SEC EDGARTimothy P. Walbert, Board member
13
SEC EDGARKeith Crandell, Board member
14
SEC EDGARJohn B. Moriarty, General counsel
15
SEC EDGARExecutive or director change; Regulation FD disclosure
16
SEC EDGARResults of operations
17
SEC EDGARBylaws or fiscal year changed
18
NasdaqNasdaq calendar
19
ClinicalTrials.govClinicalTrials.gov NCT07511361: Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
20
ClinicalTrials.govClinicalTrials.gov NCT07210723: A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
21
ClinicalTrials.govClinicalTrials.gov NCT06864104: A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
22
SEC EDGARPERCEPTIVE ADVISORS LLC SCHEDULE 13D/A on Kardigan, Inc.
23
SEC EDGARAnastasios Gianakakos SCHEDULE 13G on Kardigan, Inc.
24
SEC EDGARJay Edelberg SCHEDULE 13G on Kardigan, Inc.
25
SEC EDGARFMR LLC SCHEDULE 13G/A on Kardigan, Inc.
26
SEC EDGARARCH Venture Fund XIII, L.P. SCHEDULE 13D on Kardigan, Inc.
27
SEC EDGARHRTG GPE, LLC SCHEDULE 13G on Kardigan, Inc.
28
SEC EDGARKardigan, Inc. 10-Q filed Aug 11, 2026: shares outstanding